36 results
8-K
EX-10.1
QLGN
Qualigen Therapeutics Inc
27 Feb 24
Entry into a Material Definitive Agreement
7:00am
of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its
8-K
EX-2.1
QLGN
Qualigen Therapeutics Inc
26 Jul 23
Entry into a Material Definitive Agreement
5:25pm
authorization, manufacturing facilities compliance, packaging, good manufacturing practices, labeling, advertising, promotional practices, safety
8-K
EX-10.1
99ivhtl4k5ftkjpn
22 Dec 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-10.1
ff5mxbxu0w1jn3k m0s
1 Dec 21
Qualigen Therapeutics, Inc. Announces Closing of $8.82 Million Registered Direct Offering
3:39pm
424B5
1tqs98qfz0n5qd64n7t
1 Dec 21
Prospectus supplement for primary offering
2:28pm
10-KT
lzw agsit
31 Mar 21
Annual report (with FYE transition)
4:33pm
8-K
EX-10.1
rmmw072q 1w3b3m
18 Dec 20
Qualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct Offering
3:54pm
424B5
qtx qor163
18 Dec 20
Prospectus supplement for primary offering
1:26pm
424B5
b7l6wyo68t72s5z6 5g
2 Oct 20
Prospectus supplement for primary offering
4:24pm
8-K
EX-10.1
3ba31kw2odeb5arf8r
4 Aug 20
Qualigen Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:25pm
424B5
sfb6mi 8rb5gckeferh
4 Aug 20
Prospectus supplement for primary offering
6:16am
8-K
EX-10.1
006kg f63f8
10 Jul 20
Qualigen Therapeutics, Inc. Announces Closing of $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:40pm
424B5
yba5r4dp lh80
10 Jul 20
Prospectus supplement for primary offering
2:35pm
8-K
EX-10.1
jroap9pjzmd
9 Jul 20
Qualigen Therapeutics, Inc. Announces $8 Million
6:02am
8-K
EX-10.11
9nj4jlddpl
29 May 20
Qualigen Therapeutics Announces Merger Closing
5:03pm